CN103070878A - Compound Caulis Sinomenii tablet - Google Patents
Compound Caulis Sinomenii tablet Download PDFInfo
- Publication number
- CN103070878A CN103070878A CN2012105316073A CN201210531607A CN103070878A CN 103070878 A CN103070878 A CN 103070878A CN 2012105316073 A CN2012105316073 A CN 2012105316073A CN 201210531607 A CN201210531607 A CN 201210531607A CN 103070878 A CN103070878 A CN 103070878A
- Authority
- CN
- China
- Prior art keywords
- tablet
- blood
- uric acid
- pill
- caulis sinomenii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 8
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 12
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940116269 uric acid Drugs 0.000 claims abstract description 12
- 239000008280 blood Substances 0.000 claims abstract description 11
- 210000004369 blood Anatomy 0.000 claims abstract description 11
- 239000006187 pill Substances 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 235000012054 meals Nutrition 0.000 claims abstract description 3
- 229940079593 drug Drugs 0.000 claims abstract 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 3
- 241001643409 Sinomenium acutum Species 0.000 claims description 2
- 241000411851 herbal medicine Species 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 230000009747 swallowing Effects 0.000 claims 1
- 201000005569 Gout Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 4
- INYYVPJSBIVGPH-UHFFFAOYSA-N 14-episinomenine Natural products C1CN(C)C2CC3=CC=C(OC)C(O)=C3C31C2C=C(OC)C(=O)C3 INYYVPJSBIVGPH-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 3
- INYYVPJSBIVGPH-QHRIQVFBSA-N Sinomenine Chemical compound C([C@@H]1N(CC2)C)C3=CC=C(OC)C(O)=C3[C@@]32[C@@H]1C=C(OC)C(=O)C3 INYYVPJSBIVGPH-QHRIQVFBSA-N 0.000 description 3
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 description 3
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 3
- 229960003321 baicalin Drugs 0.000 description 3
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 3
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 3
- 229960002529 benzbromarone Drugs 0.000 description 3
- RARWEROUOQPTCJ-RBUKOAKNSA-N cepharamine Natural products C1CC2=CC=C(OC)C(O)=C2[C@@]2(CCN3C)[C@]13C=C(OC)C(=O)C2 RARWEROUOQPTCJ-RBUKOAKNSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940096978 oral tablet Drugs 0.000 description 3
- 239000007935 oral tablet Substances 0.000 description 3
- 229940023488 pill Drugs 0.000 description 3
- 229930002966 sinomenine Natural products 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 description 3
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 2
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 description 2
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 1
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a compound preparation for reducing the concentration of uric acid in the blood to treat gout, and concretely discloses a compound Caulis Sinomenii tablet. The tablet is characterized in that the components of the tablet and the proportions of the components are shown in the specification, and eight medicines which are the components are mixed according to the proportions to prepare the tablet or a pill. 0.5-1.0g of the tablet or the pill is orally taken each time, and is continuously taken three times a day after each meal for 2-3 weeks.
Description
One. technical field
The present invention relates to a kind of compound oral tablet, refer to more specifically a kind ofly can reduce uric acid concentration in the blood, treatment gout compound preparation.
Two. background technology
Gout is common chronic disease.The medicine of at present commercially available treatment gout all is difficult to radical cure gout disease, cure the symptoms, not the disease, and toxic and side effects is larger, in case easily repeatedly aggravation outbreak of gout after the drug withdrawal.
Three. summary of the invention
Technical problem to be solved by this invention is to overcome deficiency of the prior art, and a kind of safety is provided, effectively, and the oral natural medicine that toxic and side effects is little.(its English Sinomenine by name, molecular formula is C to the present invention's employing with sinomenine
19H
23NO
4, molecular weight is 329.38) and be the basis, (its English Benzbromarone by name, molecular formula is C to be equipped with benzbromarone
17H
12Br
2O
3, molecular weight is 424.08), (its English Syringin by name, molecular formula is C to Radix Et Caulis Acanthopanacis Senticosi glucoside
17H
24O
9, molecular weight is 372.37), psoralen (its English Psoralen by name, molecular weight is 186.16), (its English Baicalin by name, molecular formula is C to baicalin
21H
18O
11, molecular weight is 446.37), (its English Triptolide by name, molecular formula is C to triptolide
20H
24O
6, molecular weight is 360.4), crocetin (its English croceicacid by name), (its English Cordycepic acid by name, molecular formula is C to cordycepic acid
6H
14O
6), make oral tablet or pill, the treatment gout, uric acid concentration has special effect in the normal blood of human body to stablizing.Main component of the present invention and proportioning thereof are:
Above-mentioned eight herbal medicines in proportion proportioning be mixed and made into tablet or pill.
Sinomenine has uric acid concentration in the blood of reduction among the present invention, and antalgic and sedative, antitussive local anaesthesia, blood pressure lowering, antiinflammatory action are histamine liberators very strong in the plant.Benzbromarone is benzofuran derivative, has to suppress renal tubules to the resorption of uric acid thereby reduce uric acid concentration in the blood.Radix Et Caulis Acanthopanacis Senticosi glucoside has the effect that reduces uric acid concentration in the blood.The Fructus Psoraleae rigging has anticancer, and the diastole bronchial smooth muscle reduces the effect of uric acid concentration in the blood.Baicalin has significant biological activity, has antibacterial, diuresis, antiinflammatory, resistance attitude and spasmolysis, and has the stronger physiological potencies such as antitumor response.Triptolide has resisting rheumatoid disease is arranged, antitumaous effect.Crocetin has resisting rheumatoid disease, reduces the effect of uric acid concentration in the blood.Cordycepic acid has anti-liver tissue fibrosis, the effect of anti peroxidation of lipid.
Four. the specific embodiment:
The present invention uses 50 sick many cases, and each oral tablet or pill 0.5-1.0g swallow with 5% saleratus solution every day three times after meal, serve on 2-3 week, and the gout disease is had good curative effect,
Uric acid concentration all is controlled at normal range in one all rear blood, and toxic and side effects appears in none example.So far half a year at least after taking medicine, uric acid concentration rebound phenomena in the blood does not appear at most more than a year.
Claims (2)
1. natural drug compound preparation that reduces uric acid concentration in the blood, the one-tenth that it is characterized in that it be grouped into and proportioning as follows:
Above-mentioned eight herbal medicines in proportion proportioning be mixed and made into tablet or pill.
2. after meal with the 5% sodium bicarbonate aqueous solution compound recipe Sinomenium acutum sheet 0.5-1 of the present invention gram of swallowing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210531607.3A CN103070878B (en) | 2012-12-11 | 2012-12-11 | Compound Caulis Sinomenii tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210531607.3A CN103070878B (en) | 2012-12-11 | 2012-12-11 | Compound Caulis Sinomenii tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103070878A true CN103070878A (en) | 2013-05-01 |
| CN103070878B CN103070878B (en) | 2014-10-22 |
Family
ID=48147725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210531607.3A Expired - Fee Related CN103070878B (en) | 2012-12-11 | 2012-12-11 | Compound Caulis Sinomenii tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103070878B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306816A (en) * | 2014-10-27 | 2015-01-28 | 上海浦东高星生物技术研究所 | Chinese patent medicine for treating gout |
| CN107937201A (en) * | 2018-01-22 | 2018-04-20 | 胡江宇 | A kind of preparation method of wild grape wine |
| CN110772519A (en) * | 2019-12-02 | 2020-02-11 | 四川大学华西医院 | Application of sinomenine or salt thereof in preparing medicine for reducing level of uric acid and preventing and treating uric acid nephropathy |
| CN112451537A (en) * | 2020-11-16 | 2021-03-09 | 武汉轻工大学 | Application of baicalin in preparation of medicine for preventing and/or treating asymptomatic hyperuricemia and/or uric acid nephropathy |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1537553A (en) * | 2003-04-16 | 2004-10-20 | 冯宝泽 | Traditional Chinese medicine for treating gout exelling |
| CN1539429A (en) * | 2003-10-27 | 2004-10-27 | 中国医学科学院药物研究所 | Deoxyadenosine in aplication of preparing bypolipidemic |
| CN101380425A (en) * | 2008-10-24 | 2009-03-11 | 权吉太 | Arthrosis pill and production method thereof |
| CN101658519A (en) * | 2008-08-26 | 2010-03-03 | 天津泰普药品科技发展有限公司 | Medicinal composition for treating hyperuricemia |
-
2012
- 2012-12-11 CN CN201210531607.3A patent/CN103070878B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1537553A (en) * | 2003-04-16 | 2004-10-20 | 冯宝泽 | Traditional Chinese medicine for treating gout exelling |
| CN1539429A (en) * | 2003-10-27 | 2004-10-27 | 中国医学科学院药物研究所 | Deoxyadenosine in aplication of preparing bypolipidemic |
| CN101658519A (en) * | 2008-08-26 | 2010-03-03 | 天津泰普药品科技发展有限公司 | Medicinal composition for treating hyperuricemia |
| CN101380425A (en) * | 2008-10-24 | 2009-03-11 | 权吉太 | Arthrosis pill and production method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 张晓丽，等: "藏红花酸的研究进展", 《西北药学杂志》, vol. 23, no. 6, 31 December 2008 (2008-12-31), pages 411 - 414 * |
| 涂正伟，等: "刺五加的研究进展", 《药物评价研究》, vol. 34, no. 3, 30 June 2011 (2011-06-30), pages 213 - 216 * |
| 陈勇，等: "抗痛风颗粒中青风藤TLC鉴别与青藤碱的含量测定", 《中国实验方剂学杂志》, vol. 13, no. 6, 30 June 2007 (2007-06-30), pages 11 - 13 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306816A (en) * | 2014-10-27 | 2015-01-28 | 上海浦东高星生物技术研究所 | Chinese patent medicine for treating gout |
| CN107937201A (en) * | 2018-01-22 | 2018-04-20 | 胡江宇 | A kind of preparation method of wild grape wine |
| CN110772519A (en) * | 2019-12-02 | 2020-02-11 | 四川大学华西医院 | Application of sinomenine or salt thereof in preparing medicine for reducing level of uric acid and preventing and treating uric acid nephropathy |
| CN112451537A (en) * | 2020-11-16 | 2021-03-09 | 武汉轻工大学 | Application of baicalin in preparation of medicine for preventing and/or treating asymptomatic hyperuricemia and/or uric acid nephropathy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103070878B (en) | 2014-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103070878B (en) | Compound Caulis Sinomenii tablet | |
| CN103083429B (en) | Blood fat-reducing traditional Chinese medicine formula | |
| CN102357124B (en) | Chinese medicine combination with effects of detumescence and inflammatory resistance and preparation method thereof | |
| CN104758451A (en) | Traditional Chinese medicine composite for treating gout | |
| CN106420883A (en) | Composition with anti-gout effect and preparation method and application thereof | |
| CN102973875B (en) | Medicament for strengthening spleen, checking diarrhea and removing food retention for children | |
| CN100448464C (en) | Synergistic medicinal composition for treating hepatitis | |
| CN103585330B (en) | A kind of Chinese medicine composition for cutaneous fungal infection and preparation method thereof | |
| CN113855734B (en) | Medicine for treating diarrhea and preparation method thereof | |
| CN100475202C (en) | Medicinal composition with function of clearing away heat and toxic material | |
| CN101716259B (en) | Traditional Chinese medicine composition of effective parts for treating cough and preparation method thereof | |
| CN101607009B (en) | Pharmaceutical composition for treating cold | |
| CN100450498C (en) | Accessory medicinal composition for treating hepatitis | |
| CN101574422A (en) | Medicine composition and preparation method thereof | |
| CN108210721A (en) | A kind of Chinese medicine composition for being used to treat liver-kidney yin deficiency Hiccough and deaf | |
| CN107865932A (en) | A kind of Chinese medicine composition with effect of weight reducing | |
| CN101856408B (en) | Medicine containing Epomediol | |
| CN101721517B (en) | Pharmaceutical composition containing glucurolactone | |
| CN103536597B (en) | Application of Kadcoccitones A in preparing medicine for treating renal insufficiency | |
| CN104225014B (en) | A kind of Tibetan medicine for the treatment of diabetes | |
| CN101810779B (en) | Combination drug containing Guadisu | |
| CN103479625A (en) | Application of Fluevirosines A in preparation of blood sugar reducing medicines | |
| CN100421686C (en) | Chinese-western medicine composition for treating hepatitis | |
| CN101797339B (en) | Synergistic medicinal composition containing oleanolic acid | |
| CN108210656A (en) | A kind of Chinese medicine composition for being used to treat liver gallbladder damp-heat type Hiccough and deaf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160713 Address after: 201100, room 160, seven village, 102 Yang Luo village, Shanghai, Minhang District Patentee after: Gao Yuzhen Address before: 201200 Shanghai city Pudong New Area Chuansha 54 paper Stone Road Lane 4, Room 502 Patentee before: Shanghai Pudong Gaoxing Biotechnology Research Institute |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141022 Termination date: 20171211 |